ArticleThe Journal of infectious diseases2011
Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis.
Article in The Journal of infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes.PLoS neglected tropical diseases · 2012Pooled it
- Single-stranded DNA oligonucleotides containing CpG motifs are non-stimulatoryFrontiers in cellular and infection microbiology · 2024Article
- Evaluation of two different vaccine platforms for immunization against melioidosis and glanders.Frontiers in microbiology · 2022Article
- A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection.Vaccine · 2020Article
- Emerging role of biologics for the treatment of melioidosis and glanders.Expert opinion on biological therapy · 2019Review
- Rapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application.Virulence · 2017Article
- Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory.Journal of clinical microbiology · 2016Review
- A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei.Nanomedicine : nanotechnology, biology, and medicine · 2015Article
- Treatment and prophylaxis of melioidosis.International journal of antimicrobial agents · 2014Review
- The impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents.Journal of immunology research · 2014Review
- Monitoring Therapeutic Treatments againstPathogens (Basel, Switzerland) · 2013Article
- Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.Infection and immunity · 2013Article
- CpG adjuvant enhances the mucosal immunogenicity and efficacy of a Treponema pallidum DNA vaccine in rabbits.Human vaccines & immunotherapeutics · 2013Article
- Burkholderia vaccines: are we moving forward?Frontiers in cellular and infection microbiology · 2013Review
- Post-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomallei.PLoS neglected tropical diseases · 2013Article
- Role of RelA and SpoT in Burkholderia pseudomallei virulence and immunity.Infection and immunity · 2012Article
- Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice.Clinical and vaccine immunology : CVI · 2012Article
- Prophylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosis.PloS one · 2012Article
- Article
- Development of vaccines against burkholderia pseudomallei.Frontiers in microbiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The Gram-negative bacterium Burkholderia pseudomallei is the causative agent of melioidosis, a major cause of lethal sepsis and morbidity in endemic areas of Southeast Asia and a potential bioterrorism threat. We have used susceptible BALB/c mice to evaluate the potential of targeting vaccination and generic immunotherapy to the lung for optimal protection against respiratory challenge. Intranasal vaccination with live attenuated B. pseudomallei increased survival and induced interferon-γ-secreting T cells in the lung. Intranasal delivery of CpG oligodeoxynucleotides also provided significant protection; however, combining preexposure vaccination with CpG treatment at the time of infection or up to 18 hours after infection, provided significantly greater protection than either treatment alone. This combination prolonged survival, decreased bacterial loads by >1000-fold, and delayed the onset of sepsis. This novel approach may be applicable to other potential biodefense agents for which existing countermeasures are not fully effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.